Nervous System News and Research

Latest Nervous System News and Research

Zenvia patent application: AVANIR Pharmaceuticals receives USPTO "Notice of Allowance"

AVANIR Pharmaceuticals, Inc. today announced that it has received a “Notice of Allowance” from the United States Patent and Trademark Office (USPTO) announcing that it intends to grant the Company a new patent, extending the period of commercial exclusivity for its lead drug candidate Zenvia™ well into 2025.

8 Oct 2009

Scientists make significant advance towards a solution for neuronal repair

The repair of damaged nerve cells is a major problem in medicine today. A new study by researchers at the Montreal NeurologicaI Institute and Hospital (The Neuro) and McGill University, is a significant advance towards a solution for neuronal repair.

8 Oct 2009

Study reveals large structural differences between natural prions and man-made synthetic analogs

A collaboration between scientists at Vanderbilt University and the University of California, San Francisco has led to the first direct information about the molecular structure of prions. In addition, the study has revealed surprisingly large structural differences between natural prions and the closest synthetic analogs that scientists have created in the lab.

7 Oct 2009

Physical activity during adolescence decreases risk of glioma

While little is known about the causes of glioma, researchers at the National Cancer Institute have found that this rare but often deadly form of brain cancer may be linked to early life physical activity and height.

7 Oct 2009

Research finds 50 million people vaccinated against zoonotic brain infection

Research at the University of Liverpool has supported the vaccination of more than 50 million people against a zoonotic brain infection that affects thousands of children across Asia every year.

7 Oct 2009

Clinical trial of gene transfer therapy for advanced Parkinson's disease

Henry Ford West Bloomfield Hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer.

7 Oct 2009

Research to explore diagnosis and treatment of rare diseases

The National Institutes of Health announced today a second phase of the Rare Diseases Clinical Research Network (RDCRN) including funds for 19 research consortia.

7 Oct 2009

Catalyst Pharmaceutical raises $3.97 million from institutional investors

Catalyst Pharmaceutical Partners, Inc. today announced that it has closed its previously announced registered direct offering of 3.97 million shares of its common stock to institutional investors at a price per share of $1.00, representing gross proceeds of $3.97 million.

7 Oct 2009

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.

7 Oct 2009

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR Pharmaceuticals, Inc. today announced it will present detailed data from the Phase III confirmatory STAR trial in the treatment of pseudobulbar affect (PBA) at the 3rd World Congress on Controversies in Neurology (CONy) in Prague, Czech Republic on October 8 - 11, 2009 and the American Neurological Association (ANA) 134th Annual Meeting in Baltimore, MD on October 11 - 14, 2009.

6 Oct 2009

It is possible to communicate through power of thought alone: Study

New research from the University of Southampton has demonstrated that it is possible for communication from person to person through the power of thought alone.

6 Oct 2009

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

A new treatment option for Canadians with schizophrenia, ABILIFY(TM) (aripiprazole), is now available in Canada. For those living with this lifelong disease who may be struggling with a treatment that doesn't work for them or with side effects that are difficult to tolerate, ABILIFY offers efficacy and good safety and tolerability with limited impact on weight, blood sugar and lipids - significant clinical benefits that may help patients stay on treatment longer.

6 Oct 2009

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (“Biovail”), a subsidiary of Biovail Corporation.

6 Oct 2009

NIMH awards SRI International a $6.3M contract for study of ligands for brain imaging research

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded a $6.3 million contract by the National Institute of Mental Health (NIMH) to conduct preclinical safety studies of promising novel ligands that will be used for brain imaging research and clinical applications.

6 Oct 2009

16 Canadian students living with chronic illness to receive UCBeyond Scholarships

What would you do if you were faced with a chronic illness? Would you walk across Canada to raise awareness for Crohn's disease, build houses in developing countries despite physical pain or dedicate your career to educating young people living with the same disease as you?

6 Oct 2009

Study reveals information about molecular structure of prions

6 Oct 2009

Drivers with Parkinson's disease at greater risk of crashes on foggy days

Drivers with mild to moderate Parkinson's disease may be at higher risk of crashes on foggy days and other times of low visibility. The research, involving a driving simulation test, is published in the October 6, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

6 Oct 2009

Study shows that GSK-3 gene determines the total number of neurons required for brain

In populating the growing brain, neural stem cells must strike a delicate balance between two key processes - proliferation, in which the cells multiply to provide plenty of starting materials - and differentiation, in which those materials evolve into functioning neurons.

5 Oct 2009

New genetic alteration can cause familial cancers

Duke University Medical Center and National Cancer Institute scientists have discovered that a novel genetic alteration - a second copy of an entire gene - is a cause of familial chordoma, an uncommon form of cancer arising in bones and frequently affecting the nervous system.

5 Oct 2009

Breast milk should not be stored and fed later

The levels of the components in breast milk change every 24 hours in response to the needs of the baby. A new study published in the journal Nutritional Neuroscience shows, for example, how this milk could help newborn babies to sleep.

3 Oct 2009

Nervous System News and Research

Latest Nervous System News and Research

Zenvia patent application: AVANIR Pharmaceuticals receives USPTO "Notice of Allowance"

Scientists make significant advance towards a solution for neuronal repair

Study reveals large structural differences between natural prions and man-made synthetic analogs

Physical activity during adolescence decreases risk of glioma

Research finds 50 million people vaccinated against zoonotic brain infection

Clinical trial of gene transfer therapy for advanced Parkinson's disease

Research to explore diagnosis and treatment of rare diseases

Catalyst Pharmaceutical raises $3.97 million from institutional investors

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

It is possible to communicate through power of thought alone: Study

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

NIMH awards SRI International a $6.3M contract for study of ligands for brain imaging research

16 Canadian students living with chronic illness to receive UCBeyond Scholarships

Study reveals information about molecular structure of prions

Drivers with Parkinson's disease at greater risk of crashes on foggy days

Study shows that GSK-3 gene determines the total number of neurons required for brain

New genetic alteration can cause familial cancers

Breast milk should not be stored and fed later

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Nervous System News and Research

Latest Nervous System News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in